

## Review Article

# Myocardial Regeneration via Progenitor Cell-Derived Exosomes

**Janita A. Maring,<sup>1</sup> Christien M. Beez,<sup>1</sup> Volkmar Falk,<sup>2,3</sup> Martina Seifert,<sup>1</sup>  
and Christof Stamm<sup>1,2,3</sup>**

<sup>1</sup>*Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany*

<sup>2</sup>*German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany*

<sup>3</sup>*Deutsches Herzzentrum Berlin (DHZB), Berlin, Germany*

Correspondence should be addressed to Janita A. Maring; [Janita-aline.maring@charite.de](mailto:Janita-aline.maring@charite.de)

Received 11 August 2017; Accepted 11 October 2017; Published 23 November 2017

Academic Editor: Heinrich Sauer

Copyright © 2017 Janita A. Maring et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the past 20 years, a variety of cell products has been evaluated in terms of their capacity to treat patients with acute myocardial infarction and chronic heart failure. Despite initial enthusiasm, therapeutic efficacy has overall been disappointing, and clinical application is costly and complex. Recently, a subset of small extracellular vesicles (EVs), commonly referred to as “exosomes,” was shown to confer cardioprotective and regenerative signals at a magnitude similar to that of their donor cells. The conceptual advantage is that they may be produced in industrial quantities and stored at the point-of-care for off-the-shelf application, ideally without eliciting a relevant recipient immune response or other adverse effects associated with viable cells. The body of evidence on beneficial exosome-mediated effects in animal models of heart diseases is rapidly growing. However, there is significant heterogeneity in terms of exosome source cells, isolation process, therapeutic dosage, and delivery mode. This review summarizes the current state of research on exosomes as experimental therapy of heart diseases and seeks to identify roadblocks that need to be overcome prior to clinical application.

## 1. Introduction

Regenerative therapy has the ultimate goal of repairing damaged tissue by limiting the extent of tissue damage following injury (cytoprotection), stimulating the endogenous regenerative capacity of a tissue (regeneration), and/or providing new cells or tissues as a replacement (cell therapy, tissue engineering). Although resident cardiac progenitor cells (CPC) have been described to persist within the adult mammalian myocardium [1–3], the myocardium has no clinically relevant intrinsic regenerative capacity due to a lack of postnatal cardiomyocyte mitosis [4]. Exogenous somatic cells transplanted into the diseased human heart failed to induce a meaningful improvement of heart function in clinical trials [5–8]. Cardiomyocyte cell products derived from embryonic or induced pluripotent stem cells (ES or iPS) have not been tested yet in controlled clinical trials, largely due to the complexity and costs of a clinical-grade production process. Concerns about genomic integrity of pluripotent-derived

cells and unresolved issues such as cellular immaturity, coupling with host cells and possible arrhythmia, are difficult to rule out in suitable preclinical models.

Nevertheless, a variety of beneficial effects following experimental cell therapy in cardiac disease models has been observed even in the absence of transplanted cell persistence or stem/progenitor cell differentiation [9]. For instance, studies in which mesenchymal stromal cells (MSCs) were transplanted failed to show permanent engraftment of the transplanted cells but still yielded a sustained increase in cardiac function [10, 11]. Indeed, subsequent research has shown that conditioned medium collected from MSCs has cardioprotective effects and their secreted factors alone were already able to reduce infarct size and increase cardiac function in an animal myocardial infarction (MI) model [12, 13]. Investigations regarding the active factors secreted by the MSCs have shown that extracellular vesicles (EV) rather than single growth factors convey this beneficial effect [12].




FIGURE 1: Exosomes are formed by invaginations of intercellular vesicles such as endosomes, which then form multivesicular bodies (MVBs). Exosomes are released into the extracellular space by fusion of the MVB with the cell membrane. Recipient cells take up the exosomes through direct fusion with the cell membrane, through internalisation or through receptor-ligand interaction on the recipient cell membrane.

Intercellular communication was long thought to be restricted to single agent messengers such as secreted growth factors and cytokines. Nowadays, the mode of paracrine signalling is extended by the incorporation of EVs as a major player in cell-to-cell as well as organ-to-organ communication. Vesicular structures were found in the extracellular space (and in body fluids) consisting of exosomes (30–100 nm), microvesicles (100–1000 nm), and apoptotic bodies (up to 5000 nm) [14]. Extracellular vesicle discovery is commonly attributed to the context of platelet maturation and the first use of the term dates back to the 1970s [15]. Extracellular vesicles are surrounded by a phospholipid membrane, and they are believed to contain up to 20,000 different protein molecules with preserved catalytic and ligand-binding activities [16–18]. More recently, vesicles were shown to also contain mRNAs and miRNAs, which seem to play an important role in cell-to-cell information transfer [19]. Extracellular vesicles are secreted in a diverse manner such as secretion via multivesicular bodies or pinching from the cell membrane. Exosomes are a distinct microvesicle subpopulation due to their particular biogenesis and the lack of proteins from certain organelles such as the Golgi apparatus and the endoplasmic reticulum, which can be found in other vesicles, for example, apoptotic bodies [20, 21].

Exosomes are formed through invaginations of endosomes, forming multivesicular bodies (MVBs) in the cytoplasm. Their content of RNAs, lipids, and proteins is

partially a reflection of the composition of the cell. Therefore, part of the constituents found in exosomes is highly dependent on the state of the cell and changes upon, for example, hypoxia, mitochondrial stress, and differentiation [22]. Some components can be selectively sorted into the vesicles, for example, sorting of proteins into the exosomes is depended on the ESCRT (endosomal sorting complexes required for transport) machinery [23] or sphingolipids [24]. Interestingly, several studies have shown that the RNA content is not necessarily identical between donor cell and their secreted exosomes, since some microRNAs (miRNAs) are more abundantly present in vesicles compared to their originating cells, while others were completely absent [25–27].

Exosomes are secreted through transport and subsequent fusion of the MVBs to the cell membrane. This process is mediated by proteins of the Rab family, with Rab27A and Rab27B being the most prominent. Knockdown of either of these two proteins results in a significantly reduced exosome secretion [28, 29]. The process of exosome formation, secretion, and uptake known to date is shown in Figure 1. The bilipid membrane of the exosomes protects the content from degradation and thus enables signalling over long distances [19]. Investigations into the signalling range have revealed that the application of cells engineered to express Cre was able to rearrange the genome of susceptible cells containing a LoxP site on the contralateral site of the mice via their released EVs [30].

## 2. Suitable Cell Sources for Exosomal Therapy

Several cell sources could be used for a clinical approach with exosomes as a therapeutic agent. Multiple studies in several research areas have shown the effects of exosomes on, for instance, cell survival, angiogenesis, and migration [31, 32]. With the experience of the cells previously used in cell therapy, which were shown to be safe and effective, these donor cells are widely considered to be the most efficient sources for regenerative exosome generation (Figure 2).

The first cell type to be studied in preclinical and clinical settings for cardiac repair was bone marrow-derived cells, due to the fact that these cells are easily obtained in an autologous fashion. Even though it was hypothesized that bone marrow-derived cells were capable of transdifferentiating into cardiomyocytes [33], no conclusive evidence has been found that this is indeed the case [34, 35]. Although these cells were able to increase cardiac function when injected after myocardial infarction *in vivo* [33], they have varying results in clinical trials [5, 6].

More recently, MSCs have been investigated for clinical cardiac repair in autologous as well as allogeneic setting. In general, MSCs can be found in many tissues, such as bone marrow, adipose tissue, and cord blood. A hallmark is their capability to differentiate towards osteogenic, chondrogenic, and adipose lineages [36]. Differentiation into cardiomyocytes has so far only been seen in foetal MSCs, but with low efficiency *in vitro* [37]. The results on cardiac function in clinical trials have been very modest and not to the same extent as in the preclinical models [7, 8]. Moreover, MSCs have also been shown to not differentiate *in vivo* to cardiomyocytes and are not retained in the heart, suggesting that paracrine factors of these cells are the acting agents [10].

With the finding that the heart contains progenitor cells (CPC), actual cardiac regeneration seemed obtainable. Indeed, cardiac progenitors have the capability to differentiate into cardiomyocytes *in vitro* and *in vivo* [1–3, 38]. Moreover, they have been shown in preclinical models to be effective in increasing cardiac function after myocardial infarction [1–3, 38]. This concurred with the differentiation into cardiomyocytes and endothelial cells and, for example, an increase in angiogenesis in the borderzone of the infarction [9, 38]. Two clinical trials have been carried out so far to assess the safety of injecting cardiac progenitor cells. Both trials—CADUCEUS and SCIPIO—have indeed shown that injecting cardiac progenitor cells one month or more after myocardial infarction is safe, with some minor decreases in scar size and increases in local ejection fraction [39, 40].

Other cell sources are ES and iPS cell pluripotent stem cells, which have been under investigation for a wide range of regenerative processes since they still contain the ability to differentiate towards every cell type in the body. Therefore, pluripotent stem cells and cardiomyocytes derived from pluripotent stem cells have also been evaluated after myocardial infarction in preclinical models. In these studies, it was shown that these cells were indeed able to engraft into the heart and increase cardiac function significantly [41–44]. However, additional risks have emerged by using these cells, such as arrhythmias and teratoma formation [42–44].

## 3. Exosomes as Therapeutics in Cardiovascular Repair

Exosomes have been shown to be involved in a plethora of cellular processes, such as migration, differentiation, survival, and immune modulation [31, 32, 45]. Therefore, exosomes generated from the proper regenerative cell source could have profound beneficial effects in the regenerative processes after myocardial infarction, making them interesting new therapeutic agents. Due to the fact that the cells investigated in cell therapy after MI have been shown to convey their effects mainly through paracrine signalling, research has focused on evaluating the regenerative potential of the exosomes from these cell sources. Table 1 provides an overview of the experimental studies performed so far, their major findings, as well as involved pathways or proposed active molecules.

One of the first studies evaluating the paracrine mechanism in cardiac repair used exosomes from human MSCs. Here, they showed that injection of MSC-derived exosomes into the tail vein of mice 5 minutes before reperfusion of the cardiac tissue significantly reduced infarct size 24 hours postoperation. Additionally, animals treated with exosomes had increased cardiac function compared to control animals over a 28-day time course. Analysis of the hearts showed that in the first 24 hours, there was an increase in activation of pAkt and pGSK3 (glycogen synthase kinase 3), which are both involved in cell survival pathways, whereas immune cell infiltration was decreased [32]. In another study, the cardioprotective effect of human MSCs was compared with their exosomes, both after injection into the infarcted borderzone. Both cells and exosomes comparably decreased infarct size after 28 days and increased cardiac function. Additionally, vessel density was also increased after the treatment with exosomes [46]. This proangiogenic effect of MSC exosomes has indeed been verified *in vitro* by these and other studies, where a significant induction of proliferation, tubule formation, and migration of endothelial cells was observed [46, 47]. This effect might be explained by the presence of several proangiogenic proteins in the exosomes, such as vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 [47].

Exosomes from rat MSCs were shown to increase the proliferation, migration, and tubule formation of cardiac stem cells *in vitro*. Interestingly, it was demonstrated that several miRNAs were changed into these cells upon exosome treatment, such as upregulation of miR-147 and miR-503-3p and downregulation of miR-207, miR-326-5p, and miR-702-5p [48]. When cardiac stem cells were treated with exosomes from rat MSCs prior to injection into the heart, an increase in cardiac function and vessel density at the infarct site could be seen after 28 days [48].

Exosomes from iPS or ES cells were also able to increase proliferation and tubule formation in CPCs [49], while apoptosis was reduced *in vitro* in both CPCs and cardiomyocytes [49, 50]. Furthermore, the expression of several endothelial and cardiomyocyte genes was upregulated in CPCs after stimulation with ES-derived exosomes. When injected into the heart after MI, the exosomes were able to reduced




FIGURE 2: Several cell sources are being examined for use as an exosome therapy, most prominently cardiac progenitor cells, mesenchymal stem cells, and induced pluripotent stem cells as well as embryonic stem cells. Each of them has distinct advantages and disadvantages regarding cardiac regeneration.

TABLE 1: Overview of exosomes as therapeutics in preclinical MI studies.

Cell type	Species	Donor cell specifics	Diminished infarct size	Cardiac effect			Decreased apoptosis	Other effects	Active pathways/molecules	Ref
				Increased cardiac function	Higher vessel density	Reduced fibrosis				
MSC	Human		✓	✓	✓				[46]	
	Human		✓	✓					[32]	
	Rat	CPCs prestimulated with exosomes		✓	✓	✓			[48]	
	Mouse	Ischemic preconditioning				✓	Increase in pAkt and pGsk3, reduced immune cell infiltration	miR-22	[58]	
CPC	Human	Cardiac explant cells from cardiovascular patients		Reduced			Decrease in exosome production	IL-6	[65]	
	Human		✓	✓	✓	✓		miR-132	[53]	
	Human		✓	✓	✓	✓		miR-146a	[54]	
	Rat			✓		✓		miR-292	[52]	
	Mouse						✓	miR-451	[51]	
ES	Mouse		✓	✓	✓		✓	Increase in CPC proliferation	miR-291, miR-294, miR-295/Akt	[49]
iPS	Mouse						✓		miR-21, miR-210	[50]
Other	Human	hCD34+ SHH+						Transfer of SHH to endothelial cells	SHH	[55]
	Rat/human	Plasma from remote ischemic preconditioning	✓						Erk, Akt	[71]
	Rat	Perfused hearts with ischaemia (conditioning)	✓							[59]

apoptosis after 48 hours [50] and 4 weeks [49]. Furthermore, injection of ES-derived exosomes increased proliferation, vessel density, and cardiac function, while injection of CPCs prestimulated with ES-derived exosomes, increased cardiac function, and reduced infarct size. The cardioprotective effect could be due to the presence of several known protective miRNAs present in the exosomes, such as miR-21 and miR-210 [50]. The importance of miR-291, miR-294, and miR-295 was confirmed when the use of a miRNA mimic was able to reproduce the induction of CPC proliferation *in vitro* [49].

CPC-derived exosomes are currently being investigated regarding their regenerative potential. Mice CPC-derived exosomes have been shown to reduce the apoptosis of cardiomyocytes *in vitro* and *in vivo* after MI [51]. Exosomes from rat CPCs were able to increase tubule formation of endothelial cells. Furthermore, the mRNA levels of several fibrosis-related genes were significantly downregulated. *In vivo* analysis of these rat CPC-derived exosomes showed an increase

in cardiac function, while fibrosis was reduced [52]. Also, exosomes from human CPCs have been evaluated whether they are able to reproduce the positive effects of the originating cell type when injected after MI. Those CPC-derived exosomes were capable to reduce the infarct size in between 7 and 30 days after MI, accompanied by an increase in cardiac function and vessel density. Furthermore, fibrosis was markedly reduced [53, 54]. It became apparent that miR-146a seems to be an important mediator in those exosomes, as a mimic of the miRNA was able to partly reproduce the antiapoptotic effect of the exosomes *in vitro*. Further investigations regarding the role of miR-146a *in vivo* by a knockout mice model showed that without miR-146a infarct size was not reduced and cardiac function did not improve, while injecting a mimic or miR-146a after MI did [54]. The overall proangiogenic effect of CPC-derived exosomes has been implicated in the abovementioned studies. Indeed, exosomes from CPCs are able to promote several parameters of the angiogenesis process *in vitro*. Endothelial cells stimulated



with human CPC-derived exosomes markedly increase migration, tubule formation, and spheroid sprouting [31, 47]. Moreover, in a mouse matrigel-based plug assay, overall cell migration into the plug and blood vessel formation was increased in the presence of exosomes. Several proangiogenic factors were present in these exosomes, such as VEGF, MMP-9, and EMMPRIN (extracellular matrix metalloproteinase inducer). Knockdown of EMMPRIN showed a significant decrease in angiogenesis *in vitro* and *in vivo*, implying that EMMPRIN is a major factor in CPC-derived exosome-induced angiogenesis [47].

#### 4. Potential of Modified Exosomes

Since the protein and miRNA content of exosomes depended on the state and content of their donor cells, several approaches are possible to increase the efficiency of exosomes on cardiac repair. CD34<sup>+</sup> cells were genetically modified to overexpress sonic hedgehog (SHH), which resulted in an increased cardiac function and vessel density after MI. It was found that this was (partly) due to the fact that the exosomes from these cells contain SHH, which can be transferred to the recipient cells within the heart, and increase SHH signalling [55].

Overexpression of GATA binding protein 4 (GATA4) in rat bone marrow-derived MSCs leads to a reduction of hypoxia-induced apoptosis of cardiomyocytes when treated with the exosomes from these cells. Moreover, GATA4-overexpressing exosomes restored mitochondrial integrity and had an increase in miR-19 content. MiR-19 is an important effector in survival pathways. *In vivo* analysis indeed showed an increase in miR-19 when the GATA4-overexpressing exosomes were injected after MI. This also leads to an increase in cardiac function and a reduction in infarct size [56].

Besides genetically altering the donor cell to increase or decrease the expression of certain proteins, exosomes can also be altered by changing the conditions of the donor cell at the time of exosome generation. For example, hypoxia is well known to have profound effects on cells, and (remote) ischemic preconditioning has been shown to have positive effects in the clinic [57]. When exosomes were isolated from the hearts or MSCs that have undergone ischemic preconditioning, these exosomes reduced infarct size and fibrosis after MI [58, 59]. *In vitro*, they were able to reduce apoptosis in cardiomyocytes [58].

#### 5. Translation to Preclinical Large Animal Models

Recently, the Marban group reported on a series of experiments in a clinically relevant pig model, where exosomes secreted by human cardiosphere-derived cells were delivered either intracoronary or intramyocardial following reperfused myocardial infarction [60]. In the acute infarct model, only intramyocardial exosome injection resulted in reserved LV function. Moreover, intramyocardial injection was also beneficial in chronic ischemia. The obvious conclusion is that exosomes need to be delivered directly into the myocardium,

which may render clinical application even more complex. However, cohort size was small, and the average particle diameter was 197 nm rather than the typical diameter size of 30–100 nm. The authors attribute this to their use of nanoparticle tracking analysis, but it cannot be ruled out that this reflects a different vesicle population [60]. The notion that exosomes are poorly taken up after intracoronary delivery indeed needs serious consideration. Within tissue, cell-to-cell transfer of exosomes between neighbouring cells is feasible. For adhesion and uptake by the vascular endothelium, however, a minimum density and number of specific adhesion molecules presented on the cell surface are required. On nanoscale exosomes formed in MVBs, a small number of surface proteins may be randomly incorporated, and exosomes should transit the capillary bed at a higher speed than the entire cell. It remains to be investigated whether the exosomes secreted from stimulated cells with distinct endothelial adhesion are predisposed to be taken up by the targeted cells. Interestingly, the Marban group also showed in acute ischemia-reperfusion experiments in rats and mice that CPC-derived exosomes confer cardioprotection by modulating macrophage polarization, induced by transfer of miR-181b leading to inhibition of protein kinase C (PKC) $\delta$  [61]. Interestingly, these effects were observed after intracoronary infusion of the exosomes in a rat model and after intramuscular delivery in pigs [60, 61]. In another study, the same group implicated that the Y RNA fragment (EV-YF1) is responsible for cardiomyocyte protection from hypoxia-reoxygenation/ischemia-reperfusion injury by being transferred to macrophages and inducing IL-10 secretion [62]. The means by which exosomes modulate the local tissue immune balance via small RNAs is clearly emerging. Individual pathways and mediators can be identified in specific experimental models, but there is consensus that the multitude of exosome nucleic acids (and proteins) acting in concert are responsible for their pronounced and sustained cardioprotective effects.

#### 6. Future Perspectives

Exosomes from sources such as MSCs or CPCs have been investigated as interesting new therapeutical agents. So far, the first preclinical studies have shown that these exosomes have indeed large regenerative potential and are able to positively influence important processes after myocardial infarction. These effects were observed on a cellular as well as on the whole organ as an overall improvement in cardiac function.

*6.1. Clinical Translation and Commercial Exploitation.* A number of companies have a secured intellectual property of exosome technology, such as Esperite (immunology applications), Aegle Therapeutics (burns, chronic wounds, etc.), ReNeuron (neural stem cells), SystemsBiosciences (extracellular vesicle precipitation), Anosys (dendritic cell-derived ECV for malignancies), and Capricor. Capricor is a Cedars Sinai Medical Center Spin-off run by the Marban family that developed and evaluated cardiosphere-derived progenitor cells for treatment of postischemic myocardial dysfunction.

Their allogeneic CPC product, CAP-1002, apparently did not meet the efficacy primary outcome in a controlled clinical trial, and the company now focuses on clinical translational of their CPC-derived exosome product (CAP-2003). Their claim, that only exosomes derived from CPCs are effective in ischemic heart disease, is supported by data published by the Marban research group, [54, 60, 62]. However, other groups showed that exosomes from other cell sources are cardioprotective, too [32, 63].

**6.2. Exosomes and Immunology.** Exosomes derived from dendritic cells or B-cells were shown to present functional surface MHC class I and II antigens [17, 18]. This phenomenon is the basis for the concept of using exosomes/vesicles designed to contain specific tumour antigens as tumour vaccines. Similarly, vesicles carrying antigens of infectious pathogens may be used to elicit a specific immune response for vaccination or treatment. The current assumption is that exosomes from nonimmunological cells are immune-privileged, and indeed most animal experiments so far have been performed with exosomes derived from allogeneic or xenogeneic cells. Even if transplanted exosomes are ultimately eliminated by phagocytic cells, this does not seem to influence their therapeutic capacity. In contrast, in a recent study from Sicco et al., the immune-modulating property of exosomes from MSCs was investigated regarding their effects on macrophages. Here, they could show *in vitro* that a switch towards alternative activated macrophages can be induced by MSC-derived exosomes, which might explain to a certain extent their therapeutic potential [64]. Whether an unwanted sensitization can be induced by exosome-related alloantigens or allogeneic exosomes are less effective in allosensitized patients is not known, yet, but needs further attention.

**6.3. Autologous Exosomes.** In principle, exosomes can be obtained from autologous cells, provided that the primary cell source possesses robust viability and proliferation capacity in cell culture in order to yield sufficient high cell numbers and, if needed, responds to stimulation for collection of large quantities of conditioned media. MSCs, fibroblasts, endothelial cells, and also cells of cardiac origin (e.g., CPC) generally meet these criteria, but cultivation may be difficult or fail in patients of advanced age or severe disease, as well as a result in less effective exosomes [65]. However, the process of obtaining therapeutic doses of autologous exosomes could be time-consuming and costly, and their application in emergency situations such as acute myocardial infarction is not feasible.

**6.4. Exosomes as a Therapeutic Product.** While exosomes are not organisms, they do contain a nonuniform mix of proteins and are derived from cells that are either allogeneic or autologous but subjected to nonhomologous use. Therefore, they meet the key criteria for classification as biological medicinal products or, if derived from manipulated cells, as advanced therapeutic medicinal product (ATMP) or gene therapy products by most authorities. An algorithm for regulatory classification of extracellular vesicles has recently been proposed in a position paper of the International Society for

Extracellular Vesicles (ISEV) [66]. As outlined by Brindley et al., the characterization of clinical-grade exosomes and their cGMP-compatible production process should encompass a defined size range including the use of a standardized detection method(s), identification by defined biochemical markers, exosome purity (freedom from cells, cell debris, and macromolecules), scalable isolation methods including serum-free source cell culture, and methods for exosome stabilization and storage [67]. It has been suggested that exosomes may be commercialized as “by-products” of cell manufacturing, but we consider it likely that dedicated exosome production processes will be required. Several groups concentrate on using iPS-derived cells as donor cells to generate exosomes for therapeutic use, such as iPS-derived MSCs. The idea is to use a standardized, “perfect” cell source free from any pathogens or genetic aberrations, possibly customized to enhance exosome function, to yield a uniform exosome product that is “streamlined” in terms of compliance with regulatory demands.

**6.5. Optimizing Exosomes.** In addition to their intrinsic therapeutic potential, exosomes may be used as vehicles for delivery of small molecule drugs, proteins, and nucleic acids (comprehensively reviewed by Ha et al.) [68]. This may be particularly useful when the active compound is unstable, such as siRNA. Moreover, exosomes may enable drugs to enter the central nervous system that are not able to cross the blood-brain barrier in the “naked” form. Specific delivery of cytostatic drugs to tumour tissue via integration into exosomes has also been described [69]. Compared to artificial liposomes for drug delivery, exosomes are believed to persist longer and to possess additional biologic effects [70].

To enhance therapeutic efficacy in the heart, it has been suggested to harvest exosomes from cells that were stimulated by stressors such as hypoxia, leading to an accumulation of stress-response proteins and possibly nucleic acids. While exosomes contain integrins, not all adhesion molecules present on exosomes have been identified yet. This might be the reason that not all exosomes are effective upon systemic or intracoronary delivery, as was shown by the Marban group in a large animal myocardial infarction model [60]. However, in numerous rodent models, intravascular exosome delivery led to improved cardiac function and it is entirely unclear whether this phenomenon has specific biologic reasons or merely reflects local underdosing [32, 71]. Guiding exosomes to specific tissues and improving their uptake by manipulating their surface protein profile are a field of research that will be important for therapeutic success.

## 7. Conclusion

Extracellular vesicles, most notably exosomes, have been known for almost 50 years, but their potential for therapeutic use in regenerative medicine has only recently been acknowledged. Numerous basic research and preclinical studies have shown beneficial effects in models of different heart diseases, including the acutely or chronically ischemic heart. Compared to viable cell products, development of a readily

available off-the-self therapy should be less complex. However, as was the case with “whole cell” therapy for heart disease in the past 20 years, exosomes from easily obtainable unmodified cells may have limited therapeutic efficacy, and future clinical studies will soon clarify this. Many facets of current translational and commercial activities surrounding the use of exosomes in cardiac regeneration are evocative of the recent history of somatic cell therapy. It remains to be seen whether exosome biology indeed offers fundamental advantages and is able to make a relevant contribution to the development of novel therapies for heart disease.

## Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

## References

- [1] R. R. Smith, L. Barile, H. C. Cho et al., “Regenerative potential of cardiosphere-derived cells expanded,” *Circulation*, vol. 115, no. 7, pp. 896–908, 2007.
- [2] A. P. Beltrami, L. Barlucchi, D. Torella et al., “Adult cardiac stem cells are multipotent and support myocardial regeneration,” *Cell*, vol. 114, no. 6, pp. 763–776, 2003.
- [3] M.-J. Goumans, T. P. de Boer, A. M. Smits et al., “TGF- $\beta$ 1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes *in vitro*,” *Stem Cell Research*, vol. 1, no. 2, pp. 138–149, 2007.
- [4] S. D. Prabhu and N. G. Frangogiannis, “The biological basis for cardiac repair after myocardial infarction,” *Circulation Research*, vol. 119, no. 1, pp. 91–112, 2016.
- [5] V. Jeevanantham, M. Butler, A. Saad, A. Abdel-Latif, E. K. Zuba-Surma, and B. Dawn, “Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis,” *Circulation*, vol. 126, no. 5, pp. 551–568, 2012.
- [6] P. Nigro, B. Bassetti, L. Cavallotti, V. Catto, C. Carbuicchio, and G. Pompilio, “Cell therapy for heart disease after 15 years: unmet expectations,” *Pharmacological Research*, 2017.
- [7] A. R. Williams and J. M. Hare, “Mesenchymal stem cells,” *Circulation Research*, vol. 109, no. 8, pp. 923–940, 2011.
- [8] S. F. Rodrigo, J. Van Ramshorst, G. E. Hoogslag et al., “Intramyocardial injection of autologous bone marrow-derived *ex vivo* expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up,” *Journal of Cardiovascular Translational Research*, vol. 6, no. 5, pp. 816–825, 2013.
- [9] M. C. den Haan, R. W. Grauss, A. M. Smits et al., “Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts,” *Journal of Cellular and Molecular Medicine*, vol. 16, no. 7, pp. 1508–1521, 2012.
- [10] M. Mazo, J. J. Gavira, G. Abizanda et al., “Transplantation of mesenchymal stem cells exerts a greater long-term effect than bone marrow mononuclear cells in a chronic myocardial infarction model in rat,” *Cell Transplantation*, vol. 19, no. 3, pp. 313–328, 2010.
- [11] B. Tao, M. Cui, C. Wang et al., “Percutaneous intramyocardial delivery of mesenchymal stem cells induces superior improvement in regional left ventricular function compared with bone marrow mononuclear cells in porcine myocardial infarcted heart,” *Theranostics*, vol. 5, no. 2, pp. 196–205, 2015.
- [12] L. Timmers, S. K. Lim, F. Arslan et al., “Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium,” *Stem Cell Research*, vol. 1, no. 2, pp. 129–137, 2007.
- [13] L. Timmers, S. K. Lim, I. E. Hoefler et al., “Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction,” *Stem Cell Research*, vol. 6, no. 3, pp. 206–214, 2011.
- [14] S. Ailawadi, X. Wang, H. Gu, and G. C. Fan, “Pathologic function and therapeutic potential of exosomes in cardiovascular disease,” *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, vol. 1852, no. 1, pp. 1–11, 2015.
- [15] N. Crawford, “The presence of contractile proteins in platelet microparticles isolated from human and animal platelet-free plasma,” *British Journal of Haematology*, vol. 21, no. 1, pp. 53–69, 1971.
- [16] H. Dvorak, S. Quay, N. Orenstein et al., “Tumor shedding and coagulation,” *Science*, vol. 212, no. 4497, pp. 923–924, 1981.
- [17] L. Zitvogel, A. Regnault, A. Lozier et al., “Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes,” *Nature Medicine*, vol. 4, no. 5, pp. 594–600, 1998.
- [18] G. Raposo, H. W. Nijman, W. Stoorvogel et al., “B lymphocytes secrete antigen-presenting vesicles,” *Journal of Experimental Medicine*, vol. 183, no. 3, pp. 1161–1172, 1996.
- [19] H. Valadi, K. Ekstrom, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells,” *Nature Cell Biology*, vol. 9, no. 6, pp. 654–659, 2007.
- [20] C. Théry, S. Amigorena, G. Raposo, and A. Clayton, “Isolation and characterization of exosomes from cell culture supernatants,” *Current Protocols in Cell Biology*, Chapter 3, pp. 1–29, 2006.
- [21] D. K. Jeppesen, A. Nawrocki, S. G. Jensen et al., “Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors,” *Proteomics*, vol. 14, no. 6, pp. 699–712, 2014.
- [22] P. Kucharzewska, H. C. Christianson, J. E. Welch et al., “Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 18, pp. 7312–7317, 2013.
- [23] J. Klumperman and G. Raposo, “The complex ultrastructure of the endolysosomal system,” *Cold Spring Harbor Perspectives in Biology*, vol. 6, no. 10, article a016857, 2014.
- [24] K. Trajkovic, C. Hsu, S. Chiantia et al., “Ceramide triggers budding of exosome vesicles into multivesicular endosomes,” *Science*, vol. 319, no. 5867, pp. 1244–1247, 2008.
- [25] M. Mittelbrunn, C. Gutiérrez-Vázquez, C. Villarroya-Beltri et al., “Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells,” *Nature Communications*, vol. 2, p. 282, 2011.
- [26] J. Liao, R. Liu, L. Yin, and Y. Pu, “Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing,” *International Journal of Molecular Sciences*, vol. 15, no. 9, pp. 15530–15551, 2014.



- [27] B. S. Hong, J.-H. Cho, H. Kim et al., "Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells," *BMC Genomics*, vol. 10, no. 1, p. 556, 2009.
- [28] M. Ostrowski, N. B. Carmo, S. Krumeich et al., "Rab27a and Rab27b control different steps of the exosome secretion pathway," *Nature Cell Biology*, vol. 12, no. 1, pp. 19–30, 2010.
- [29] J. Kowal, M. Tkach, and C. Théry, "Biogenesis and secretion of exosomes," *Current Opinion in Cell Biology*, vol. 29, pp. 116–125, 2014.
- [30] A. Zomer, C. Maynard, F. J. Verweij et al., "In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior," *Cell*, vol. 161, no. 5, pp. 1046–1057, 2015.
- [31] K. R. Vrijzen, J. P. G. Sluiter, M. W. L. Schuchardt et al., "Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells," *Journal of Cellular and Molecular Medicine*, vol. 14, no. 5, pp. 1064–1070, 2010.
- [32] F. Arslan, R. C. Lai, M. B. Smeets et al., "Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury," *Stem Cell Research*, vol. 10, no. 3, pp. 301–312, 2013.
- [33] D. Orlic, J. Kajstura, S. Chimenti et al., "Bone marrow cells regenerate infarcted myocardium," *Nature*, vol. 410, no. 6829, pp. 701–705, 2001.
- [34] C. E. Murry, M. H. Soonpaa, H. Reinecke et al., "Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts," *Nature*, vol. 428, no. 6983, pp. 664–668, 2004.
- [35] L. B. Balsam, A. J. Wagers, J. L. Christensen, T. Kofidis, I. L. Weissman, and R. C. Robbins, "Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium," *Nature*, vol. 428, no. 6983, pp. 668–673, 2004.
- [36] M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," *Cytotherapy*, vol. 8, no. 4, pp. 315–317, 2006.
- [37] A. A. Ramkisoensing, D. A. Pijnappels, S. F. A. Askar et al., "Human embryonic and fetal mesenchymal stem cells differentiate toward three different cardiac lineages in contrast to their adult counterparts," *PLoS One*, vol. 6, no. 9, article e24164, 2011.
- [38] A. M. Smits, L. W. van Laake, K. den Ouden et al., "Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium," *Cardiovascular Research*, vol. 83, no. 3, pp. 527–535, 2009.
- [39] K. Malliaras, R. R. Makkar, R. R. Smith et al., "Intracoronary cardiosphere-derived cells after myocardial infarction," *Journal of the American College of Cardiology*, vol. 63, no. 2, pp. 110–122, 2014.
- [40] A. R. Chugh, G. M. Beache, J. H. Loughran et al., "Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial," *Circulation*, vol. 126, no. 11, Supplement 1, pp. S54–S64, 2012.
- [41] M. A. Laflamme, K. Y. Chen, A. V. Naumova et al., "Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts," *Nature Biotechnology*, vol. 25, no. 9, pp. 1015–1024, 2007.
- [42] O. Caspi, I. Huber, I. Kehat et al., "Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts," *Journal of the American College of Cardiology*, vol. 50, no. 19, pp. 1884–1893, 2007.
- [43] J. J. H. Chong, X. Yang, C. W. Don et al., "Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts," *Nature*, vol. 510, no. 7504, pp. 273–277, 2014.
- [44] G. Blin, D. Nury, S. Stefanovic et al., "A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates," *The Journal of Clinical Investigation*, vol. 120, no. 4, pp. 1125–1139, 2010.
- [45] S. Yu, H. Cao, B. Shen, and J. Feng, "Tumor-derived exosomes in cancer progression and treatment failure," *Oncotarget*, vol. 6, no. 35, pp. 37151–37168, 2015.
- [46] S. Bian, L. Zhang, L. Duan, X. Wang, Y. Min, and H. Yu, "Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model," *Journal of Molecular Medicine*, vol. 92, no. 4, pp. 387–397, 2014.
- [47] K. R. Vrijzen, J. A. Maring, S. A. J. Chamuleau et al., "Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis via EMMPRIN," *Advanced Healthcare Materials*, vol. 5, no. 19, pp. 2555–2565, 2016.
- [48] Z. Zhang, J. Yang, W. Yan, Y. Li, Z. Shen, and T. Asahara, "Pre-treatment of cardiac stem cells with exosomes derived from mesenchymal stem cells enhances myocardial repair," *Journal of the American Heart Association*, vol. 5, no. 1, article e002856, 2016.
- [49] M. Khan, E. Nickoloff, T. Abramova et al., "Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction," *Circulation Research*, vol. 117, no. 1, pp. 52–64, 2015.
- [50] Y. Wang, L. Zhang, Y. Li et al., "Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium," *International Journal of Cardiology*, vol. 192, pp. 61–69, 2015.
- [51] L. Chen, Y. Wang, Y. Pan et al., "Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury," *Biochemical and Biophysical Research Communications*, vol. 431, no. 3, pp. 566–571, 2013.
- [52] W. D. Gray, K. M. French, S. Ghosh-Choudhary et al., "Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology," *Circulation Research*, vol. 116, no. 2, pp. 255–263, 2015.
- [53] L. Barile, V. Lionetti, E. Cervio et al., "Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction," *Cardiovascular Research*, vol. 103, no. 4, pp. 530–541, 2014.
- [54] A. G.-E. Ibrahim, K. Cheng, and E. Marbán, "Exosomes as critical agents of cardiac regeneration triggered by cell therapy," *Stem Cell Reports*, vol. 2, no. 5, pp. 606–619, 2014.
- [55] A. R. Mackie, E. Klyachko, T. Thorne et al., "Sonic hedgehog-modified human CD34+ cells preserve cardiac function after acute myocardial infarction," *Circulation Research*, vol. 111, no. 3, pp. 312–321, 2012.

- [56] B. Yu, H. W. Kim, M. Gong et al., "Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection," *International Journal of Cardiology*, vol. 182, pp. 349–360, 2015.
- [57] Y. J. Cho, E.-H. Lee, K. Lee et al., "Long-term clinical outcomes of remote ischemic preconditioning and postconditioning outcome (RISPO) trial in patients undergoing cardiac surgery," *International Journal of Cardiology*, vol. 231, pp. 84–89, 2017.
- [58] Y. Feng, W. Huang, M. Wani, X. Yu, and M. Ashraf, "Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22," *PLoS One*, vol. 9, no. 12, article e88685, p. e114139, 2014.
- [59] Z. Giricz, Z. V. Varga, T. Baranyai et al., "Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles," *Journal of Molecular and Cellular Cardiology*, vol. 68, pp. 75–78, 2014.
- [60] R. Gallet, J. Dawkins, J. Valle et al., "Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction," *European Heart Journal*, vol. 38, no. 3, pp. 201–211, 2017.
- [61] G. de Couto, R. Gallet, L. Cambier et al., "Exosomal microRNA transfer into macrophages mediates cellular postconditioning clinical perspective," *Circulation*, vol. 136, no. 2, pp. 200–214, 2017.
- [62] L. Cambier, G. de Couto, A. Ibrahim et al., "Y RNA fragment in extracellular vesicles confers cardioprotection via modulation of IL-10 expression and secretion," *EMBO Molecular Medicine*, vol. 9, no. 3, pp. 337–352, 2017.
- [63] R. C. Lai, F. Arslan, M. M. Lee et al., "Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury," *Stem Cell Research*, vol. 4, no. 3, pp. 214–222, 2010.
- [64] C. Lo Sicco, D. Reverberi, C. Balbi et al., "Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization," *Stem Cells Translational Medicine*, vol. 6, no. 3, pp. 1018–1028, 2017.
- [65] A. E. Mayfield, M. E. Fitzpatrick, N. Latham et al., "The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells," *Stem Cell Research & Therapy*, vol. 7, no. 1, p. 60, 2016.
- [66] T. Lener, M. Gimona, L. Aigner et al., "Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper," *Journal of Extracellular Vesicles*, vol. 4, no. 1, article 30087, 2015.
- [67] D. A. Brindley, K. Bure, A. Smith James et al., "Extracellular vesicles commercial potential as byproducts of cell manufacturing for research and therapeutic use," *Bioprocess International*, 2015, August 2017, <http://www.bioprocessintl.com/manufacturing/cell-therapies/extracellular-vesicles-commercial-potential-as-byproducts-of-cell-manufacturing-for-research-and-therapeutic-use/>.
- [68] D. Ha, N. Yang, and V. Nadithe, "Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges," *Acta Pharmaceutica Sinica B*, vol. 6, no. 4, pp. 287–296, 2016.
- [69] K. Tang, Y. Zhang, H. Zhang et al., "Delivery of chemotherapeutic drugs in tumour cell-derived microparticles," *Nature Communications*, vol. 3, p. 1282, 2012.
- [70] K. B. Johnsen, J. M. Gudbergsson, M. N. Skov, L. Pilgaard, T. Moos, and M. Duroux, "A comprehensive overview of exosomes as drug delivery vehicles — endogenous nanocarriers for targeted cancer therapy," *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, vol. 1846, no. 1, pp. 75–87, 2014.
- [71] J. M. Vicencio, D. M. Yellon, V. Sivaraman et al., "Plasma exosomes protect the myocardium from ischemia-reperfusion injury," *Journal of the American College of Cardiology*, vol. 65, no. 15, pp. 1525–1536, 2015.